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Background: Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication
and increase walking distance in patients with peripheral arterial disease (PAD). At the time of approval, the United States
Food and Drug Administration required an additional long-term safety study to evaluate the effect cilostazol on
mortality.
Methods: A total of 1899 subjects with a clinical diagnosis of PAD and symptoms of claudication were screened for
participation in a randomized, double-blinded, placebo-controlled safety study of cilostazol. The intent-to-treat (ITT)
population, which was the primary analysis (n  1435), was defined as all randomized patients who received at least one
dose of study medication and included patients who were followed up >30 days after discontinuation of study drug. A
total of 717 patients received cilostazol and 718 received placebo. Cilostazol was administered at a primary dose of 100
mg twice daily. The dose could be reduced to 50 mg twice daily if patients experienced an adverse event that might have
been drug related.
Results: Long-term adherence to study medication was poor, with >60% of participants discontinuing therapy by 36
months. The mortality analysis therefore focused on deaths during the period on-treatment, defined as the period during
which the study drug was taken plus a 30-day follow-up period after dosing. Total patient-years of exposure were 1046
on-treatment for cilostazol and 1090 for placebo. On-treatment, there were 18 deaths on cilostazol and 19 deaths on
placebo for a hazard ratio of 0.99 (95% confidence interval [CI], 0.52-1.88). Cardiovascular deaths on-treatment
occurred in 14 patients on cilostazol and 14 on placebo. In the full ITT population at 36 months, there were 101 deaths,
49 on cilostazol and 52 on placebo, with hazard ratio of 0.94 (95% CI, 0.64-1.39). Thus, most deaths occurred >30 days
after study drug discontinuation. Serious bleeding events affected 18 patients taking cilostazol in the on-treatment
population and 22 taking placebo. The rates of bleeding events were similar in patients who used aspirin, aspirin plus
clopidogrel, or anticoagulants at anytime during the course of the study
Conclusions: This long-term study demonstrated no safety signal for cilostazol on all-cause or cardiovascular mortality.
The study, however, was underpowered to detect a small adverse impact of cilostazol on mortality (hazard ratio upper
bound of the 95% CI was 1.88 in the on-treatment population). Serious bleeding events appeared not to be increased by
cilostazol. ( J Vasc Surg 2008;47:330-6.)Peripheral artery disease (PAD) is a prevalent manifes-
tation of cardiovascular disease that is associated with sig-
nificant long-term morbidity and mortality.1,2 A variety of
therapies have been developed to treat the limitation in
exercise performance, community walking ability, and re-
duced quality of life associated with claudication, the major
symptomatic manifestation of PAD.3
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330Cilostazol was approved by the United States Food and
Drug Administration (FDA) to treat the symptom of clau-
dication on the basis of an extensive efficacy database
substantiating treatment benefit on improvements in peak
exercise performance and quality of life in patients with
claudication.4,5 Cilostazol, however, is a member of the
phosphodiesterase-III drug class, and other drugs from this
class have been associated with excess mortality when used
in patients with heart failure. An example is the long-term
administration of milrinone for the treatment of heart
failure, which was associated with a statistically significant
28% increase in all-cause mortality.6
Although the randomized trials evaluating the efficacy
of cilostazol in patients with claudication did not suggest an
increased risk, a total of only 16 deaths occurred in the
entire safety data base of 2702 patients followed up to 6
months.7 Despite the balance in these events between drug
and placebo, the few number of deaths could not exclude
more than a twofold increased mortality risk in the patients
evaluated for efficacy.8 Therefore at the time of approval,
the FDA required an additional long-term safety study of
cilostazol.9
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controlled study was initiated to evaluate the long-term safety
of cilostazol in patients with PAD. The CASTLE (Cilostazol:
A Study in Long-term Effects) study had a primary objective
to evaluate all-cause mortality, with secondary aims to evaluate
cardiovascular mortality as well as the tolerability of cilostazol
in patients followed up for approximately 3 years. This study
tested the hypothesis that all cause mortality would be similar
between patients randomized to cilostazol compared with
placebo.
METHODS
Study design and management. This was a phase 4
(postmarketing) multicenter, randomized, double-blind,
placebo-controlled, parallel-arm study comparing the ef-
fects of cilostazol vs placebo in patients with claudication
secondary to PAD. All sites obtained institutional review
board approval of the protocol, and patients signed in-
formed consent before their participation (Appendix, on-
line only). Patients who met inclusion/exclusion criteria
underwent a 30-day single-blind placebo run-in phase.
Subjects who failed to comply with at least 70% of their
prescribed regimen were withdrawn from the study. The
remaining subjects had a measurement of their ankle-
brachial index (ABI) and were randomized.
Patients were followed up to 3.5 years and were seen in
the office every 26 weeks. Additional assessments were
made by telephone every 13 weeks interspersed between
the office visits. If the patient prematurely discontinued the
study medication, telephone assessments were made every
13 weeks to evaluate the patient for mortality until the
conclusion of the study.
The study was managed by Pharmaceutical Products
Development, Inc, Morrisville, North Carolina. This in-
cluded site monitoring of 100% of the source documents,
data management, and statistical analysis.
Inclusion/exclusion criteria. Inclusion criteria in-
cluded subjects aged 17 years old with a history of inter-
mittent claudication secondary to PAD as diagnosed by a
physician (specific ABI criteria for inclusion were not de-
fined). Patients taking aspirin, clopidogrel, pentoxifylline,
or anticoagulants were eligible for participation. Exclusion
criteria included women who were pregnant or breastfeed-
ing, patients currently or previously using of cilostazol, use
of an investigational drug in the past 30 days, consumption
of grapefruit juice, or patients found to be noncompliant
during the 30-day single-blind, run-in phase. Patients with
current congestive heart failure of any severity, as assessed
by the site investigator, were excluded, but those with a
history of heart failure who had recovered were eligible for
enrollment.
Dosing. The study drug or matching placebo was
administered orally as two 50-mg tablets twice a day (total
daily dose, 200 mg) at least 30 minutes before or 2 hours
after breakfast and dinner. Patients could reduce their dose
to 1 tablet (50 mg of cilostazol or placebo) twice a day if
they experienced an adverse event that in the view of the
investigator was drug-related and there was concern forcontinued participation in the study. The reduced dose (1
tablet twice a day) could also be administered in patients
taking medications that inhibited cytochrome P-450 isoen-
zymes 3A4 or 2C19, or both, determined by the judgment
of the site investigator. In the patients randomized to
placebo, 16% decreased their dose to 1 tablet twice a day
and in those randomized to drug, 15% decreased their dose
to 50 mg twice a day. Compliance with medication was
assessed with pill counts at each follow-up visit.
At the end of the placebo run-in, median compliance
was 96.0% in the overall population. Six months after
randomization, median compliance was 95% on cilostazol
and 96% on placebo. At the final study visit (or early
termination), median compliance was 93% on drug and
94% on placebo. Thus, the patients analyzed on-treatment
had a high degree of drug compliance (using the pill count
method) during the treatment period.
Because the primary intent of this study was to evaluate
safety, a data monitoring committee was retained to over-
see the conduct and safety of the trial.
Definition of outcome events. After completion of
the trial and the protocol-specified analyses, the sponsor
formed a Publications Committee (Drs. Hiatt, Money, and
Brass) to disseminate the results. Dr Money was the prin-
cipal investigator for one of the study sites. Dr Hiatt was a
subprincipal investigator for the Colorado site, but Dr
Brass had no involvement with the study until after its
completion. The committee had full access to study data
and final approval of the current manuscript.
The study’s primary objective was to assess the safety of
cilostazol, defined as all-cause mortality, in patients with
PAD. Given the high discontinuation rate of the study
medication and that most deaths occurred 30 days after
discontinuation of study drug, the committee determined
that the original intent-to-treat (ITT) analysis would not
provide a full assessment of cilostazol safety or risk. There-
fore, the committee used a primary analysis based on deaths
that occurred while patients were taking the study medica-
tion plus a 30-day period designed to capture deaths that
might have resulted from exposure to the study medica-
tion; hereafter, this is regarded as the “on-treatment” pe-
riod. The original, prospectively defined ITT population
was also evaluated and defined as all randomized patients
who received at least one dose of study medication. Also
tabulated were deaths occurring in the ITT population
during the entire study period, including those 30 days
after study medication discontinuation.
The Publication Committee reviewed all deaths to
categorize those that were cardiovascular, defined as sud-
den death, myocardial infarction, stroke, and heart failure.
This blinded, post hoc review was limited in scope because
available information was from the site’s adverse event
narrative. These narratives were obtained from the case
report forms from the sites. Assignment of a death as
cardiovascular was done by the majority opinion after inde-
pendent review by the committee members.
Definition of adverse events. Adverse and serious
adverse events were reported on a descriptive basis by
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to standard definitions from the International Conference
on Harmonization of Technical Requirements for Reg-
istration of Pharmaceuticals for Human Use guide-
lines.10 All adverse events were recorded when patients
were on-treatment through 14 days after discontinua-
tion of treatment. Nonfatal adverse events were not
monitored after drug discontinuation. Serious adverse
bleeding events were defined as hemorrhages that were
fatal, life-threatening, required or prolonged hospitaliza-
tion, caused significant disability, or were medically sig-
nificant in the judgment of the site investigator. As
noted, patients were monitored for up to 42 months to
ascertain mortal events.
Serious adverse bleeding events were further catego-
rized in the subgroups of patients who were also noted to
be taking aspirin, clopidogrel, or anticoagulants (warfarin
or heparin). However, the temporal association of the
bleeding adverse event in relation to the concomitant use of
an antithrombotic drug (as well as the duration of the
antithrombotic therapy) could not be ascertained from the
information recorded.
Sample size and change in study management. The
study assumed a 4.5% annual mortality rate, which was
anticipated to result in 185 deaths after a mean follow-up of
34 months. This mortality rate was based on historic data at
the time the study was designed.2,11 This would assure a
95% power to detect a 75% difference in hazard rates
between the groups randomized to cilostazol or placebo at
a significance level of 0.05 for a two-sided comparison.
Using these estimates, a recruitment of 1434 subjects (717
per group) was projected based on a 34-month study with
an accrual period of 18 months.
The first patient visit occurred on May 25, 2001, and
recruitment was completed by September 2003; however,
by March 22, 2004 (34 months after first randomization),
there were 80 deaths. To achieve the protocol-specified
number of deaths, it would have been necessary to continue
the study for several more years. With the lower than
predicted death rate and higher than predicted dropout
rate, the sponsor decided that it was not feasible to con-
tinue the study until the planned number of events had
occurred. On July 7, 2004, the sponsor reached agreement
with the FDA to terminate the study early. The last patient
visit was November 3, 2004, at a time when the study had
accrued 101 deaths.
Analysis plan. Baseline demographics, risk factors, co-
morbid conditions, and medications (Table I) were com-
pared with an unpaired t test. Analyses of the primary
outcomes were performed on the ITT population, which
was defined as all randomized patients who received at least
one dose of drug. The primary analysis (specified post hoc)
was limited to the on-treatment period defined as the
period during which the patient took study medication plus
a 30-day follow-up period. This was a time to event analysis
for all-cause mortality, and survival curves were generated
using Kaplan-Meier product limit estimates, and the treat-
ment groups were compared using a log-rank test. The nullhypothesis that the relative mortality hazard ratio of cilosta-
zol to placebo is 1.0 (ie, that the hazards are equal in the
two groups) was tested at the P  .05 level (two-sided)
using the log-rank statistic. The 95% confidence interval
(CI) for the hazard ratio was provided from the Cox
proportional hazards regression model. No covariate or
prognostic factor was used in the primary analysis. Second-
ary analyses were conducted on the full ITT population
using the samemethods (this was the primary analysis in the
original protocol).
RESULTS
The study screened 1899 subjects, of which 1795
entered the baseline run-in period and a final total of 1439
were randomized. Four patients, however, did not receive
the study drug, so the ITT population consisted of 717
randomized to cilostazol and 718 randomized to placebo
for a total of 1435 patients. By 34 months after the first
patient was randomized, less than half of the projected
number of deaths had occurred and the discontinuation
rate from study drug was high, which led to study termina-
tion in November 2004, as already described. As a result,
the study was underpowered to meet its primary end point,
but inferences with respect to cilostazol effects on mortality
Table I. Baseline demographics of all randomized
patients in the intention-to-treat population
Characteristics Cilostazol Placebo P
Demographics
Number 717 718
Age, years  SD 66.5  10.2 65.9  10.5 .215
Sex (male), No (%) 470 (65.6) 470 (65.5) .998
Race, No (%)
Non-Hispanic white 566 (78.9) 570 (79.4) .857
Black 116 (16.2) 117 (16.3)
Hispanic 30 (4.2) 24 (3.3)
Other 5 (0.7) 7 (1.0)
Weight, kg  SD 84.6  19.5 84.6  18.8 .985
Ankle-brachial index* 0.74  0.23 0.76  0.24
Risk factors, No. (%)
Cigarette smoking
Never 106 (14.8) 99 (13.8) .488
Former 406 (56.6) 394 (54.9)
Currently 205 (28.6) 225 (31.3)
Diabetes 271 (37.8) 242 (33.7)
Hypertension 591 (82.4) 582 (81.1)
Hypercholesterolemia 588 (82.0) 560 (78.0)
Comorbid conditions,
No. (%)
Myocardial infarction 210 (29.3) 208 (28.9)
Stroke 74 (10.3) 76 (10.6)
Congestive heart failure 34 (4.7) 35 (4.9)
Medications at baseline,
No. (%)
Aspirin 526 (73.4) 504 (70.2)
Clopidogrel 195 (27.2) 198 (27.6)
Warfarin 86 (12.0) 92 (12.8)
Statins 506 (70.6) 509 (70.9)
*Excludes 7 patients with an ankle-brachial index 1.40 at baseline.could be described by the 95% CI of the hazard ratio.
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66 years, 66% were men, and 79% were non-Hispanic
white. The ABI was 0.74 0.23 in patients randomized to
cilostazol and 0.76 0.24 in those randomized to placebo.
All baseline demographics were similar between groups
(Table I). The baseline prevalence of cardiovascular risk
factors was also similar between groups: 86% of the patients
were either current or former smokers, 36% had diabetes
mellitus, almost 30% had had a prior myocardial infarction,
and 10% had a history of a stroke. Although active conges-
tive heart failure was an exclusion criterion, almost 5% of
the patients enrolled had a history of congestive heart
failure that was clinically resolved.
Antiplatelet use was common at baseline and equal in
both groups. Aspirin was also being taken by 73% of
patients randomized to cilostazol and in 70% of patients
taking the placebo. Clopidogrel use was less common than
aspirin, but equal in both groups. Approximately 12% of
patients were taking warfarin anticoagulation. More than
70% of both groups were taking statins. Thus, most of the
patients were receiving standard risk reduction therapies
(antiplatelet drugs and statins).
The probability of discontinuation from the study was
68% in the cilostazol group and 64% in the placebo group at
36 months. The discontinuation hazard ratio for cilostazol
compared with placebo was 1.064 (95% CI, 0.925-1.224;
P  .39). The high dropout rate (early termination) was
primarily driven by patient withdrawal of consent (16%),
adverse events (18%), or other reasons (10%). The median
length of drug exposure was 537 days for the cilostazol
group and 558.5 days for the placebo group (Table II).
This represented cumulative exposures of 1046 patient-
Table II. Mortality during the on-treatment period
(receiving study medication plus 30 days) and mortality
during the intention-to-treat period
Mortality Cilostazol Placebo
All cause mortality on-treatment
Median time, d 537 558.5
Deaths, No. 18 19
Event rate/person-year 1.72 1.74
Total patient-years exposure 1046 1090
Cardiovascular mortality on-treatment
Deaths, No. 14 14
Event rate/person-year 1.34 1.28
All-cause mortality-ITT
Median time, d 778 778
Deaths, No. 49 52
Event rate/100 person-years 3.31 3.50
Total patient-years exposure 1480 1486
Cardiovascular mortality-ITT
Deaths, No. 28 33
Event rate/person-year 1.89 2.22
ITT, Intention to treat.years on cilostazol and 1090 patient-years on placebo.At the conclusion of the study, vital status was un-
known in 92 subjects (45 on cilostazol and 47 on placebo)
in the ITT population. In those subjects, 78 withdrew
complete consent, 13 were lost to follow-up, and one was
terminated from the study by the site investigator. Only 24
patients (1.7%) were completely lost to follow-up, and of
those, vital status was not known in only six patients at
study termination (2 on cilostazol, 4 on placebo).
A total of 37 deaths occurred in the on-treatment
population, with 18 deaths on cilostazol and 19 on
placebo (Table II). This resulted in a mortality hazard
ratio of 0.99 (95% CI, 0.52-1.88, P  .97). Fig 1 shows
all-cause survival curves on cilostazol or placebo during
the on-treatment period. Given that 25% of patients had
an ABI 0.90, a sensitivity analysis was performed by
removing those and repeating the primary analyses for
the on-treatment population. In the 703 patients who
had an ABI value 0.90, there were a total of 31 events.
The hazard ratio for all cause mortality was 1.16 (95%
CI, 0.57-2.36).
A total of 101 deaths occurred in the ITT population,
including 49 on cilostazol and 52 on placebo (Table II).
The all-cause mortality hazard ratio for cilostazol compared
with placebo was 0.94 (95% CI, 0.64-1.39, P  .77). The
hazard ratio for cardiovascular deaths was 1.054 (95% CI,
0.502-2.210; P .89) in the on-treatment population and
0.852 (95% CI, 0.515-1.410; P  .533) in the ITT popu-
lation (Table II).
Adverse events were generally balanced between
groups. Table III presents the adverse events that affected
5% of either group with a ratio 1.50 between groups,
serious adverse events that affected 1% of either group
with a ratio2.00 between groups, and adverse events that
led to discontinuation that affected 1% of either group
with a ratio 2.00 between groups. As previously de-
scribed, headache was common on cilostazol, affecting
10.5% compared with 4.9% of those on placebo. Diarrhea
was also common on cilostazol, affecting 10.9% of patients
compared with 6.7% of patients on placebo. Palpitations
were also noted numerically more often on cilostazol, and
Fig. All cause mortality30 days after the last dose of drug in the
on-treatment population.bronchitis numerically more often on placebo. Serious ad-
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whereas serious adverse events numerically less common on
cilostazol compared with placebo were cerebrovascular ac-
cidents, carotid artery stenosis, femoral artery occlusions,
and cardiac arrest, although there were small absolute
numbers of events in these categories. Adverse events lead-
ing to discontinuation on cilostazol included edema, head-
ache, and diarrhea.
Rates of serious bleeding events were similar between
treatment groups, affecting 2.5% of patients on cilostazol
and 3.1% of patients on placebo (Table IV). Fifteen patients
randomized to cilostazol who were also taking aspirin had
serious bleeding events, an identical number of hemor-
rhages as in patients randomized to placebo who were also
taking aspirin. There were no differences in serious bleed-
ing events between groups in the patients who also were
taking aspirin and clopidogrel or anticoagulants.
DISCUSSION
Cilostazol is indicated for the treatment of the symptom
Table III. Selected adverse events, serious adverse
events, and events leading to discontinuation
Adverse event Cilostazol Placebo Ratio
Minor events, No (%)*
Headache 75 (10.5) 35 (4.9) 2.14
Palpitations 38 (5.3) 18 (2.5) 2.12
Diarrhea 78 (10.9) 48 (6.7) 1.63
Bronchitis 23 (3.2) 37 (5.2) 0.62
Serious events, No (%)†
Dyspnea 7 (1.0) 3 (0.4) 2.50
Cerebrovascular accident 7 (1.0) 15 (2.1) 0.48
Carotid artery stenosis 5 (0.7) 11 (1.5) 0.47
Femoral artery occlusion 3 (0.4) 7 (1.0) 0.40
Cardiac arrest 2 (0.3) 7 (1.0) 0.30
Events leading to discontinuation,
No. (%)‡
Edema 10 (1.4) 0 (0)
Headache 15 (2.1) 2 (0.3) 7.00
Diarrhea 20 (2.8) 5 (0.7) 4.00
*Adverse events are reported that affected 5% of either group with a ratio
1.50 between groups.
†Serious adverse events are reported that affected 1% of either group with
a ratio 2.00 between groups.
‡Adverse events that led to discontinuation are reported that affected1% of
either group with a ratio 2.00 between groups.
Table IV. Serious bleeding events
Events
Cilostazol,
No (%)
Placebo,
No (%)
Serious bleeding events* 18 (2.5) 22 (3.1)
On aspirin 15 (2.1) 15 (2.1)
On aspirin  clopidogrel 3 (0.4) 7 (1.0)
Anticoagulated 6 (0.8) 9 (1.3)
*Serious bleeding adverse events were recorded only during treatment and
14 days of discontinuation of study drug; however, the timing of the
serious bleeding event relative to the administration of the concomitant
medication of aspirin, clopidogrel, or anticoagulants was not recorded.of claudication in patients with PAD; however, the long-termsafety of this drugwas not known at the timeof FDAapproval.
This study demonstrated that all-cause mortality during drug
administration was similar between cilostazol and placebo,
both on-treatment and when followed up to 42 months.
On-treatment, the point estimate of the hazard ratio was 0.99
and more important, the upper bound of the 95% CI was
1.88. Analysis of cardiovascular mortality gave similar results.
These findings indicate no signal of safety concern with
cilostazol in the population studied; however, owing to the
limited number of deaths accrued, the study could not ex-
clude a modest adverse mortality effect.
The demographics of the current population were typical
of previous studies of cilostazol and other claudication
drugs.12-17 These populations have included subjects aged in
their mid-60s, who were predominantly male and non-
Hispanic white. The patients also had a predominance of
cardiovascular risk factors that increased their risk of cardio-
vascular events. The mean ABI in the current study was also
typical of patients enrolled in studies to evaluate claudication
therapies; therefore, this study evaluated a representative pop-
ulation of patients with claudication at risk for cardiovascular
events. In that context, the neutral effect of cilostazol on
major cardiovascular events andmortality in the current study
is reassuring with respect to its current clinical use.
Previous trials of claudication drugs have focused on
efficacy and therefore have typically not enrolled sufficient
patients to provide a full view of safety. When mortality event
rates were pooled from published claudication studies, the
overall mortality rate was 1.9 deaths per 100 patient-years. 18
This value is in a similar range as the all causemortality rates in
the on-treatment population in CASTLE. Themortality rates
in claudication studies may be lower than previous natural
history studies owing to selection bias of enrolling patients
who can perform a treadmill test into a claudication study,
exclusion of patients with themost serious comorbidities, and
high compliance with other risk-reduction strategies. Approx-
imately 75% of the all-cause mortality in CASTLEwas cardio-
vascular. Although the all-cause mortality rates were appar-
ently higherwhenpatientswere followedup longer in the ITT
population, the cardiovascular rates remained relatively simi-
lar. This suggests a change in the rate of noncardiovascular
deaths over time, but any change in cause-specific death over
extended follow-up periods in patients with PADwould need
to be confirmed.
The original concerns about mortality risk with
phosphodiesterase inhibitors were raised in the placebo-
controlled Prospective Randomized Milrinone Survival
Evaluation (PROMISE) study of oral milrinone in 1088
patients with class III or IV heart failure followed up for a
median of 6 months.6 The study accumulated 295 deaths
with a hazard ratio for mortality on milrinone of 1.28 and
an upper 95% CI of 1.61 (P  .038). Most of the excess
deaths were in patients with New York Heart Association
functional class IV heart failure. This raised the concern
during the FDA discussions on the approval of cilostazol
that there could be a class effect for phosphodiesterase
inhibitors increasing risk of death in all patients with car-
diovascular disease, including PAD.9 The excess mortality
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experience with phosphodiesterase inhibitors in patients
with heart failure. A meta-analysis of 8408 patients with
heart failure identified that the these drugs were associated
with an increased of 17% (upper 95% CI, 1.30) for all cause
mortality.19
However, several important distinctions exist between the
use of milrinone in heart failure and cilostazol in claudication.
The PROMISE study evaluated a much sicker population of
patients, where 295 deaths were accumulated on-treatment,
in contrast with only 37 deaths on-treatment in CASTLE.
The greater number of events in the PROMISE study pro-
vides more certainty in the point estimate of excess risk.
Although CASTLE had many fewer events, in contrast to
PROMISE, the point estimate for all-cause mortality on-
treatment was 0.99. Thus, although cilostazol is a phospho-
diesterase III inhibitor, no signal of increased risk was evident
when used in patients with PAD without heart failure.
Adverse events were common in all patients enrolled in
the study. Formal statistical testing of any adverse event
outcomes between drug and placebo was not prespecified;
therefore, the current adverse event rates are descriptive in
nature. In that context, cilostazol was associated with head-
ache, palpitations, and diarrhea, as previously described.7
Serious adverse events were also similar between groups but
with numerically fewer cerebral and peripheral arterial
events in patients randomized to cilostazol. Adverse events
leading to premature termination were also expected
(headache and diarrhea), but edema as a cause of discon-
tinuation from cilostazol has not been previously described.
Of importance was that adverse bleeding events and serious
adverse bleeding events were similar between cilostazol and
placebo whether patients were also taking other antiplatelet
or anticoagulant drugs. A previous study in patients with
PAD found the addition of cilostazol to background ther-
apy with either aspirin or clopidogrel did not further in-
crease the bleeding time.20 The lack of increased bleeding
risk with cilostazol in patients taking other antiplatelet
drugs in CASTLE is thus consistent with this previous
report. Therefore, cilostazol did not appear to increase the
risk of bleeding, even in patients taking background anti-
platelet or anticoagulant therapy.
This study had several limitations. The anticipated
number of deaths was not achieved, and thus, the study was
underpowered to test its primary end point. Despite that
limitation, the very neutral point estimate of the hazard
ratio and the 95% CIs for all-cause and cardiovascular
mortality on-treatment do exclude a clinically meaningful
level of increased risk on cilostazol.
In addition, most study deaths occurred 30 days after
discontinuation of the study medication. Because these deaths
were unlikely to be attributable to the study drug, they could
have masked any signal generated during the on-treatment
period. This necessitated a post hoc change in the primary
analysis to an on-treatment population that reflects actual
drug exposure and therefore more accurately reflects drug
risk.The large number of dropouts from the ITT popula-
tion was due to a variety of causes, but was most commonly
related to withdrawal of consent, adverse events, and other
factors. The patients who dropped out were well balanced
between drug and placebo, particularly in the patients who
terminated early for whom vital status was not known.
Given the overall balance of deaths on treatment between
drug and placebo, it is unlikely that the absence of infor-
mation on vital status from these patients in the ITT
population would have impacted the overall results.
The study also suffered from lack of a formal adjudica-
tion of fatal and serious nonfatal events. Patients with
clinical evidence of heart failure were excluded, and so the
results cannot be generalized to that population. Also, a
number of patients were enrolled who did not have an ABI
0.90, and additional clinical criteria for the diagnosis of
PAD (imaging, prior revascularization, or noninvasive lab-
oratory) were not available. Despite that limitation, the
point estimate for all-cause mortality was similar to that in
the larger populations. Finally, the temporal association of
a serious bleeding event to exposure to an antiplatelet or
anticoagulant drug could not be ascertained.
In summary, cilostazol was well tolerated and was not
associated with increased risk of mortality or bleeding. The
expected side effects of headache, diarrhea, and possibly
edema were observed on cilostazol.
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Investigator name Site/location
Elia Abboud, MD Cardiology Associates of Mobile, Mobile, Ala
Peter Abel, MD Cardiovascular Institute of the South, Morgan City, La
Dennis Abella, DO Radiant Research Alexian Brothers, Elk Grove Village, Ill
Ramon Acevedo, MD Allegiance Internal Medicine Specialists, Wauwatosa, WI
Donald Akers, MD Tulane Hospital and Clinic, New Orleans, La
Jeffrey Alexander, MD Metrohealth Medical Center, Cleveland, Ohio
Amjad Al Mahameed, MD The Cleveland Clinic Foundation, Cleveland, Ohio
John Angeloni, MD City Line Family Medicine, Bala Cynwyn, Pa
Hisham Bassiouny, MD University of Chicago Hospital, Chicago, Ill
Braden Batkoff, MD Spokane Cardiology, Spokane, Wash
Dalton Benson, MD DMI Health Care Group, Inc., Largo, Fla
Scott Berman, MD Southern Arizona Vascular Medicine, Tuscon, Ariz
Yuri Bermudez, MD Pharr, Tex
David Bernstein, MD Morton Plant Mease Primary Care, Clearwater, Fla
Jon Bittrick, MD Upstate Cardiology, Greenville, SC
Victor Bradley, MD LaPalma Clincal Research, Inc., McAllen, Tex
David Calhoun, MD University of Alabama at Birmingham, Birmingham, Ala
Harold Carlson, MD Cardiac Disease Specialists, Atlanta, Ga
Jeffrey Carr, MD, FACC Cardiovascular Associates of East Texas, Tyler, Tex
Mahesh Changlani, MD Cardiovascular Institute of the South, New Iberia, La
Andy Chiou, MD Wilford Hall Medical Center, Lackland Airforce Base, Tex
Steven Chrysant, MD Oklahoma Cardiology HTN Center, Oklahoma City, Okla
Mei-Yu Chuang, MD, PhD Western Piedmont Heart Center, Lenoir, NC
Patrick Clagett, MD UT Southwestern Medical Center, Dallas, Tex
William Clouse, MD Wilford Hall Medical Center, Lackland Airforce Base, Tex
Peter Cowen, MD Medical Specialists of the Palm Beaches, Atlantis, Fla
Linda Crouse, MD Kramer & Crouse Cardiology, Shawnee Mission, Kan
Fred Cucher, MD Phoenix Heart, PLLC, Glendale, Ariz
Charles Curry, MD Florida Heart Group, Orlando, Fla
Scott Davis, MD Arkansas Cardiology Clinic, Little Rock, Ark
Steven Deak, MD Somerset, NJ
Steven R. Deitcher, MD The Cleveland Clinic Foundation, Cleveland, Ohio
Garth Denyer, MD Oaks Medical Center, Spring, Tex
Bart Denys, MD Cardiovascular Institute of the South, Thibodeaux, La
Pratik Desai, MD Cary Cardiology, Cary, NC
Peter Dews, III, MD Williams Medical Clinic, Northville, Mich
Maciej Dryjski, MD, PhD Kaleida Health - Millard Filmore Hospital, Buffalo, NY
Marck Entrup, DO Cox Health Systems, Springfield, Mo
Peter Fail, MD Cardiovascular Institute of the South, Houma, La
Jeffrey Friedlander, MD Medical Care Clinics of America, Tampa, Fla
Roy Fujitani, MD University of California, Irvine, Orange, Calif
Raul Gaona, MD Pro-Research Group, LLC, San Antonio, Tex
Greg Geary, MD St. Vincent Medical Center, Portland, Ore
Jeffrey Geohas, MD Radiant Research, Chicago, Ill
William George, MD Professional Medical Research, Cadillac, Mich
Marc Glickman, MD Virginia Vascular Associates, Norfolk, Va
Ian Gordon, MD VA Long Beach Healthcare System, Long Beach, Calif
Ronald Gove, MD Jersey Research Foundation, Inc, Egg Harbor Township, NJ
Bruce Greenspahn, MD Lutheran General Hospital, Park Ridge, Ill
William Gries, MD Radiant Research Alexian Brothers, Elk Grove Village, Ill
Leonard Gutnick, MD Care Trends, Sioux Falls, SD
Phillip Hale, MD Danville Regional Medical Center, Danville, Va
Louis I. Heller, MD Cardiac Disease Specialists, Atlanta, Ga
Jeffrey Hendel, MD Cardiology Consultants Medical Group, Los Angeles, Calif
Charles Herring, MD, FACP New Hannover Medical Research, Wilmington, NC
Steven Hersh, MD Lutheran General Hospital, Park Ridge, Ill
Thomas Hilton, MD Jacksonville Heart Center Research, Jacksonville, Fla
Alan Hirsch, MD University of Minnesota, Minneapolis, Minn
Randall Huling, MD Desoto Research Center, Olive Branch, Miss
Gary Hunt, MD Horizon Research Center, Inc., Blue Ridge, Ga
Robert Hye, MD Kaiser Permanente, San Diego, Calif
William Jacobs, MD CDS Research, Atlanta, Ga
Dearing Johns, MD University of Virginia Hospital, Charlottesville, Va
Vikram Kashyap, MD Wilford Hall Medical Center, Lackland Airforce Base, Tex
David Kenton, MD Deerfield Beach Cardiology Associates, Deerfield Beach, Fla
Cardiology Associates, San Diego, Calif
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Investigator name
Waqar Khan, MD
M. Akram Khan, MD
Michael Koren, MD
Gary Ledley, MD
Robert Levin, MD
Pavel Levy, MD
Michael Lilly, MD
Nolan Mayer, MD, PharmD
Brent T. cLaurin, MD, FACC
Joseph McShannic, MD
Leslie Miller, MD
Chitta Mohapatra, MD
Samuel Money, MD
Ted Monitz, MD, FACC
David Morin, MD
Reynaldo Mulingtapang, MD
Ryan Neal, MD
Jeri Norman, DO
Mandeep Oberoi, MD
Dharmendra Patel, MD
Rolf Paulson, MD
John Pittman, MD
James Poindexter, MD
Larry Presant, MD
Joseph Puma, DO, FACC
Mansoor Quershi, MD
George Raad, MD
Salvador Recio, MD
Bernard Reen, MD
Judith Regensteiner, PhD
Peter Roan, MD
Mark Round, MD
John Rozanski, MD
John Rubino, MD
Michael Salrin, DO
Joel Schneider, MD
Charles Schulman, MD
Gregg Schuyler, MD
Timothy Sheehan, MD
Peter Sheehan, MD
Stephen Sigal, MD
Stuart Simon, MD
Jeffrey Snell, MD
David Stebbins
Mark Stich, DO
Dennis Stone, MD
Neil Strickman
Sharad Swami, MD
Paul Thompson, MD
Philip Totonelly, MD, FACP
Nicholas Twidale, MD, PhD
George Vellanikaran, MD
Ralph Vicari, MD
Nampalli Vijay, MD
Krishnaswami Vijayaraghavan, MD
Craig Walker, MD
John Walker, MD
Joseph Wasselle, MD
Kevin Weber, MD
Joel Weinberger, DO
Robert Weiss, MD
Laurence Yellen, MDSite/location
Tomball, Tex
North Dallas Research Associates, McKinney, Tex
Jacksonville Center for Clinical Research, Jacksonville, Fla
Philadelphia, Pa
JFK Medical Pavilion 1, Palm Springs, Fla
Hypertension & Vascular Disease Center, Winston-Salem, NC
University of Maryland Hospital, Baltimore, Md
Ventura Cardiology Consultants, Ventura, Calif
Upstate Cardiology, Greenville, SC
Summa Health System, Akron, Ohio
University of Minnesota, Minneapolis, Minn
Cardiology Associates, PC, Johnson City, NY
Ochsner Clinic, New Orleans, La
CDS Research, Atlanta, Ga
Tricities Medical Associates, Bristol, Tenn
Heart & Vascular Institute of Florida, LLC, St. Petersburg, Fla
Baylor College of Medicine, Houston, Tex
Medical Care Clinics of America, Tampa, Fla
Elizabeth, NJ
NEA Clinic, Jonesboro, Ark
Altru Health Systems Research Center, Grand Forks, ND
Putnam North Family Medical Center, Oklahoma, Okla
Ga Vascular Surgery, Atlanta, Ga
Centre for Health Care Medical Associates, San Diego, Calif
Advanced Health Institute, Galax, Va
Michigan heart, PC, Ypsilanti, Mich
Metrolina Medical Research Associates, Charlotte, NC
Houston Physician Medical Associates, Humble, Tex
Mid-Carolina Cardiology, Charlotte, NC
University of Colorado Health Sciences Center, Denver, Colo
Treasure Valley Cardiology, Boise, ID
Osceola Physician Management, Kissimmee, Fla
North Broward Hospital District, Fort Lauderdale, Fla
Multi-Speciality Research Associates of North Carolina, Raleigh, NC
Shawnee Family Medicine Clinic, Shawnee, Okla
Wake heart Associates, Raleigh, NC
Cardiology Associates of Greater Boston, Brookline, Mass
Heart & Vascular Institute of Florida, LLC, St. Petersburg, Fla
Rock Island Health Center, El Reno, Oklla
Hospital for Joint Diseases, New York, NY
Cardiovascular Associates of East Texas, Tyler, Tex
Radiant Research, Austell, Ga
Rush Presbyterian St. Luke’s Medical Center, Chicago, Ill
Clincare Fall River, LLC, Fall River, Mass
Jacksonville Center for Clinical Research, Jacksonville, Fla
Columbus Internal Medicine, Columbus, Ind
St. Luke’s Episcopal Hospital, Houston, Tex
Prime Care Clinical Research, Clinton, Okla
Harford Hospital, Hartford, Conn
South Island Medical Associates, PC, Far Rockaway, NY
Great Plains Regional Hospital, Elk City, Okla
Cardiac Disease Specialist, Fayetteville, Ga
MichMass Century Research Associates, Denver, Colo
Western Cardiology Associates, Denver, Colo
Arizona Heart Institute, Phoenix, Ariz
Cardiovascular Institute of the South, Lafayette, La
Ormond Memorial Hospital, Ormond Beach, Fla
Osler Clincal Research, Melbourne, Fla
West Front Primary Care, Traverse City, Mich
Center for Family Practice and Sports Medicine, Kissimmee, Fla
Androscoggin Cardiology Associates, Auburn, Me
